It is possible to prepare antisera that recognize individual members of a family of hybridoma proteins in which all members of the family express the cross-reactive idiotype (IdCR) characteristic of the A/J anti-Ars response. These hybridoma-specific reagents also recognize a small percentage of the IdCR+ anti-Ars antibodies, which constitute the normal A/J anti-Ars response. Thus, the previously reported sequence heterogeneity of our IdCR+ hybridoma proteins actually represents components of the normal A/J anti-Ars response. Determinants associated with one particular IdCR+ hybridoma protein, 36-71 (Id36-71), were found on approximately 0.01 to 5.0% of the IdCR+ antibodies in all of the A/J hyperimmune sera that were examined. Determinants associated with 2 other IdCR+ hybridoma proteins, 16-46-4-8 (Id16-46) and 44-10 (Id44-10) were also found in almost all A/J immune sera, again at various concentrations. These results indicate that the heritable trait (IdCR) is expressed as a large number of antibody sequences that probably arise from the somatic diversification of a limited number of germ line genes. The pattern of diversification is qualitatively similar among individual mice but varies with regard to the relative proportions of the individual antibody components.
Download full-text PDF |
Source |
---|
Front Microbiol
January 2025
Jiangsu Engineering Research Center of Biological Data Mining and Healthcare Transformation, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Introduction: Timely and accurate diagnosis is crucial for the effective treatment and prevention of brucellosis. Current serological diagnostics, primarily based on lipopolysaccharide (LPS), suffer from cross-reactivity with other Gram-negative bacteria, which limits their specificity. Periplasmic protein 26 (BP26), a highly immunogenic antigen found in , has emerged as a promising alternative for enhancing diagnostic specificity.
View Article and Find Full Text PDFJ Allergy Clin Immunol
January 2025
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN; Department of Pharmacology, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN.
Background: Studies of human IgE and its targeted epitopes on allergens have been very limited. We have an established method to immortalize IgE encoding B cells from allergic individuals.
Objective: To develop an unbiased and comprehensive panel of peanut-specific human IgE mAbs to characterize key immunodominant antigenic regions and epitopes on peanut allergens to map the molecular interactions responsible for inducing anaphylaxis.
APMIS
January 2025
Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India.
Development of antibodies for clinical use is a complex process involving numerous aspects, with antigen specificity being the most important. Initially, polyclonal antibodies, that can recognize multiple specific and nonspecific antigens (polyreactive), were developed and were very effective in the treatments. Later on, the polyspecificity/polyreactivity of these polyclonal antibodies (binding to multiple antigens) raised concerns about therapeutic efficacy because of their nonspecific interactions and challenges, such as development of immune complexes, batch-to-batch variability.
View Article and Find Full Text PDFJ Virol
January 2025
State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Science, Wuhan, China.
Unlabelled: The emergence of novel variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) continues to pose an ongoing challenge for global public health services, highlighting the urgent need for effective therapeutic interventions. Neutralizing monoclonal antibodies (mAbs) are a major therapeutic strategy for the treatment of COVID-19 and other viral diseases. In this study, we employed hybridoma technology to generate mAbs that target the BA.
View Article and Find Full Text PDFBK polyomavirus (BKV) causes polyomavirus-associated nephropathy (PyVAN) and polyomavirus-associated hemorrhagic cystitis (PyVHC) following kidney transplantation and allogeneic hematopoietic stem cell transplantation (HST). BKV strains fall into four distinct genotypes (BKV-I, -II, -III, and -IV) with more than 80% of individuals are seropositive against BKV-I genotype, while the seroprevalence of the other four genotypes is lower. PyVAN and PyVHC occurs in immunosuppressed (e.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!